Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain)

Vaccine

Volumn 29, Issue 52, 2011, Pages 9640-9648

  Díez Domingo, Javier ^a   Ridao López, Manuel ^a,b   Gutiérrez Gimeno, M Victoria ^a   Puig Barberá, Joan ^a   Lluch Rodrigo, Jose A ^c   Pastor Villalba, Eliseo ^c  

^a Centro Superior de Investigacion en Salud Publica   (Spain)

^b INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^c Direccion General de Salud Publica   (Spain)

Author keywords

Cost effectiveness; Pharmacoeconomic assessment; Pneumococcal conjugate vaccine; Spain

Indexed keywords

PNEUMOCOCCUS VACCINE; THIRTEEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTEREMIA; CHILD; DATA BASE; DEATH; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITAL; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENINGITIS; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SCHOOL CHILD; SEROTYPE; SPAIN; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SPAIN; VACCINATION; YOUNG ADULT;

EID: 82555168283     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.038     Document Type: Article

References (52)

1. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999, 5:336-345.
2. European Medicine Agency [Homepage]. Prevenar. Summary of Product Characteristics. London: EMA 2006. Available at [cited 17.09.10, accessed 20.11.10]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000323/WC500041563.pdf.
3. De Carvalho Gomes H., Muscat M., Monnet D.L., Giesecke J., Lopalco P.L. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Euro Surveill 2009, 14:19159.
4. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011, 10:187-199.
5. Hsu H.E., Shutt K.A., Moore M.R., Beall B.W., Bennett N.M., Craig A.S., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
6. Deceuninck G., De Wals P., Boulianne N., De Serres G. Effectiveness of pneumococcal conjugated vaccine using a 2+1 infant Schedule in Quebec, Canada. Pediatr Infect Dis J 2010, 29:546-549.
7. Casado-Flores J., Rodrigo C., Arístegui J., Martínón J., Fenoll A., Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. J Pediatr Infect Dis 2008, 27:1020-1022.
8. Singleton R.J., Hennessy T.W., Bulkow L.R., Hammitt L.L., Zulz T., Hurlburt D.A., et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007, 297:1784-1792.
9. Muñoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
10. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
11. Harboe Z.B., Valentiner-Branth P., Benfiled T.L., Christensen J.J., et al. Early effectiveness of heptavalent conjugates pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28:2642-2647.
12. Isaacman D.J., McIntosh E.D., Reinert R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugates vaccines. Int J Inf Dis 2010, 14:197-209.
13. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsene J.P., et al. Immunogenicity of 10-valent Pneumococcal non-typeable Haemophilus inflluenciae protein D Conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM Vaccine. Pediatr Infect Dis J 2009, 28:66-76.
14. European Medicine Agency [Homepage],. Prevenar 13. Summary of Product Characteristics. London: EMA 2010. Available at [cited 17.09.10, accessed 20.11.10]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001104/WC500057247.pdf.
15. Dirección General de Salud Pública. área de Epidemiología [Homepage]. Informe anual enfermedad neumococica invasiva. Valencia: Servicio de vigilancia y control epidemiológico; 2008. Available at [cited 26.06.10, accessed 20.11.10]. http://www.sp.san.gva.es/DgspPortal/docs/Inf_Enf_Neumo_Inv_2008.pdf.
16. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25:1355-1367.
17. Rozenbaum M.H., Hoek A.J., Hak E., Postma M.J. Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar). Vaccine 2010, 28:2367-2369.
18. Asensi F., De Jose M., Lorente M., Moraga F., Ciuryla V., Arikan S., et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 2004, 7:36-51.
19. Isaacman D.J., Strutton D.R., Kalpas E.A., Horowicz-Mehler N., Stern L.S., Casciano R., et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther 2008, 30:341-357.
20. Rozenbaum M.H. Cost effectiveness of pneumococcal vaccination among Dutch infants: an economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:2509.
21. Rubin J.L., McGarry L.J., Strutton D.R., Klugman K.P., Pelton S.I., Gilmore K.E., et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643.
22. Dirección General de Salud Pública. Generalitat Valenciana [Homepage]. Conjunto Minimo de Bases de Datos de la Comunidad Valenciana. Valencia; 2010. Available at [cited 20.09.10, accessed 20.11.10]. http://www.sp.san.gva.es/.
23. Dagan R., Givon-Lavi N., Greenberg D., Fritzell B., Siegrist C.A. Nasopharyngeal carriage of Streptococcus pneumoniae shortly before vaccination with a pneumococcal conjugate vaccine causes serotype-specific hyporesponsiveness in early infancy. J Infect Dis 2010, 201:1570-1579.
24. Garcés-Sánchez M.D., Díez-Domingo J., álvarez de Labiada T., Planelles V., Graullera M., Baldo J.M., et al. Epidemiología e impacto de la otitis media aguda en la comunidad Valenciana. An Pediatr (Barc) 2004, 60:125-132.
25. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
26. Dirección General de Salud Pública área de Epidemiología [Homepage]. Análisis de Vigilancia Epidemiológica (AVE). Valencia; 2010. Available at [cited 20.09.10, accessed 20.11.10]. http://www.sp.san.gva.es/sscc/portEntrada.jsp%3FCodPor=121%26Opcion=SANMS51000%26Pag=punto.jsp%3FCodPunto=1581%26MenuSup=SANMS50000%26Seccion=SANPS5A000%26Nivel=2%26Opcion=SANMS51000.
27. Vestrheim D.F., Hoiby E.A., Aaberge I.S., Caugant D.A. Impact of a pneumococcal conjugate vaccination program on carriage among children in Norway. Clin Vaccine Immunol 2010, 17:325-334.
28. Harboe Z.B., Valentiner-Branth P., Benfield T.L., Christensen J.J., Andersen P.H., Howitz M., et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination of invasive disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010, 28:2642-2647.
29. Ruckinger S., Van der Linden M., Reinert R.R., Von Kries R., Burckhardt F., Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27:4136-4141.
30. Ihekweazu C.A., Dance D.A., Pebody R., George R., Smith M.D., Waight P., et al. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: south west England 1996-2005. Epidemiol Infect 2008, 136:1096-1102.
31. Salleras L., Dominguez A., Ciruela O., Izquierdo C., Borrás E. Grupo de Trabajo del Sistema de Notificación Microbiológica de Cataluña [Impact of 7-valent pneumococcal conjugate vaccination in a population with low to intermediate vaccination levels]. Enferm Infect Microbiol Clin 2009, 27:275-277. [Spanish].
32. Garcés-Sánchez M.D., Díez-Domingo J., Ballester Sanz A., Peidró Boronat C., García López M., Antón Crespo V., et al. Epidemiology of community-acquired pneumonia in children aged less than 5 years old in the Autonomous Community of Valencia (Spain). An Pediatr (Barc) 2005, 63:125-130.
33. Shouval D.S., Greenberg D., Givon-Lavi N., Porat N., Dagan R. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Pediatr Infect Dis J 2009, 28:277-282.
34. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000, 19(March (3)):187-195.
35. Boletín Oficial del Estado [Homepage]. Ley 16/2008, de 22 de diciembre, de Medidas Fiscales, de Gestión Administrativa y Financiera, y de Organización de la Generalitat. Madrid; 2008. Available at [cited 30.09.10, accessed 20.11.10]. http://www.boe.es/boe/dias/2009/01/31/pdfs/BOE-A-2009-1603.pdf.
36. Oostenbrook R., Moll H., Essink-Bot M.L. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol 2002, 55:791-799.
37. Erickson L.J., De Wals P., McMahon J., Heim S. Complications of meningococcal disease in college students. Clin Infect Dis 2001, 33:737-739.
38. Benett J.E., Summer W., Downs S.M., Jaffe D.M. Parents' utilities for outcomes of occult bacteremia. Arch Pediatr Adolesc Med 2000, 154:43-48.
39. Oh P.I., Maerov, Pritchard D., Knowles S.R., Einarson T.R., Shear N.H. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin Ther 1996, 18:160-182.
40. Prieto L., Sacristán J.A., Pinto J.L., Badia X., Antoñanzas F., del Llano J. Analysis of costs and results of the economic assesment of health interventions. Med Clin (Barc) 2004, 122:423-429.
41. Ministerio de Sanidad, Política social e Igualdad [Homepage]. Coberturas de vacunación. Madrid: Dirección General de Salud Pública; 2010. Available at [cited 02.10.10, accessed 20.11.10]. http://www.msc.es/profesionales/saludPublica/prevPromocion/vacunaciones/coberturas.htm.
42. Sacristan J., Oliva J., Del Llano J., Prieto L., Pinto J. Qué es una tecnología eficiente en España?. Gac San. 2002, 16:334-343. [Spanish].
43. Díez-Domingo J., Pereiró I., Morant A., Gimeno C., Lerma M., Oyagüez I., et al. Epidemiology of invasive Streptococcus pneumoniae infections in children in Spain, 1996-1998. J Infect 2002, 45:139-143.
44. Fenoll A., Jado I., Vicioso D., Perez A., Casal J. Evolution of Streptococcus pneumoniae. Serotype and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998, 36:3447-3454.
45. Dirección General de Salud Pública. Generalitat Valenciana [Homepage]. Informe anual enfermedad neumococica invasiva. Valencia: Servicio de vigilancia y control epidemiológico; 2009. Available at [cited 26.06.10, accessed 20.11.10]. http://www.sp.san.gva.es/DgspPortal/docs/Inf_Enf_Neumo_Inv_2009.pdf.
46. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16:816-823.
47. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., Douville-Fradet M., et al. Pneumonia after Implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008, 27:963-968.
48. Van Gils E.J.M., Veenhoven R.H., Hak E., Rodenburg G.D., Bogaert D., Ljzerman P.F., et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children. A randomized controlled trial. JAMA 2009, 302:159-167.
49. Gimenez-Sanchez F., Kieninger D., Kueper K., et al. Immunogenicity of Infanrix hexa antigens when given concomitantly with 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers. IDSA 47th annual meeting 2009, [abstract 1194].
50. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11(10):760-768.
51. Wiertsema S.P., Baynam G., Khoo S.K., Veenhoven R.H., van Heerbeek N., Zhang G., et al. Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response. Vaccine 2007, 25:306-313.
52. Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, Castillo F, Hernández T, et al. Invasive Streptococcus pneumoniae serotype distribution among hospitalized pediatric population in Madrid May 2007-April 2008. 27th annual meeting of the European society for pediatric infectious diseases. 2009, Brussels, Belgium.